Compare Stocks: BPMUF, VKTX, XENE, and VCYT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPMUF Basilea Pharmaceutica	$76.25	$72.76	$59.29 ▼ $77.40	$1.00B	0.22	1 shs	10 shs
VCYT Veracyte	$45.81	$44.66	$29.45 ▼ $60.91	$3.68B	1.95	1.44 million shs	1.04 million shs
VKTX Viking Therapeutics	$29.94	$33.35	$25.77 ▼ $43.15	$3.77B	0.66	8.07 million shs	6.34 million shs
XENE Xenon Pharmaceuticals	$38.02	$56.32	$36.07 ▼ $72.66	$3.68B	0.6	2.62 million shs	1.94 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPMUF Basilea Pharmaceutica	0.00%	-1.49%	-1.49%	+26.50%	+12.55%
VCYT Veracyte	0.00%	+0.84%	+7.71%	-21.00%	+27.25%
VKTX Viking Therapeutics	0.00%	-15.80%	-14.14%	-22.66%	+0.74%
XENE Xenon Pharmaceuticals	0.00%	+2.92%	-36.37%	-37.20%	-4.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPMUF Basilea Pharmaceutica	$76.25	$72.76	$59.29 ▼ $77.40	$1.00B	0.22	1 shs	10 shs
VCYT Veracyte	$45.81	$44.66	$29.45 ▼ $60.91	$3.68B	1.95	1.44 million shs	1.04 million shs
VKTX Viking Therapeutics	$29.94	$33.35	$25.77 ▼ $43.15	$3.77B	0.66	8.07 million shs	6.34 million shs
XENE Xenon Pharmaceuticals	$38.02	$56.32	$36.07 ▼ $72.66	$3.68B	0.6	2.62 million shs	1.94 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPMUF Basilea Pharmaceutica	0.00%	-1.49%	-1.49%	+26.50%	+12.55%
VCYT Veracyte	0.00%	+0.84%	+7.71%	-21.00%	+27.25%
VKTX Viking Therapeutics	0.00%	-15.80%	-14.14%	-22.66%	+0.74%
XENE Xenon Pharmaceuticals	0.00%	+2.92%	-36.37%	-37.20%	-4.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPMUF Basilea Pharmaceutica	0.00	N/A	N/A	N/A
VCYT Veracyte	2.82	Moderate Buy	$55.78	21.76% Upside
VKTX Viking Therapeutics	2.75	Moderate Buy	$99.67	232.89% Upside
XENE Xenon Pharmaceuticals	2.94	Moderate Buy	$70.27	84.82% Upside

Current Analyst Ratings Breakdown

Latest BPMUF, VKTX, XENE, and VCYT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/28/2026	XENE Xenon Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$90.00
9/24/2026	VCYT Veracyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
9/23/2026	VKTX Viking Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$83.00 ➝ $87.00
9/22/2026	VKTX Viking Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$120.00
9/22/2026	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/22/2026	VKTX Viking Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/18/2026	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/18/2026	XENE Xenon Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$69.00 ➝ $64.00
9/18/2026	XENE Xenon Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$90.00 ➝ $46.00
9/18/2026	XENE Xenon Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$90.00 ➝ $46.00
9/18/2026	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$81.00 ➝ $70.00

(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPMUF Basilea Pharmaceutica	$280.43M	3.58	$3.85 per share	19.81	$11.73 per share	6.50
VCYT Veracyte	$517.15M	7.12	$1.49 per share	30.75	$16.57 per share	2.76
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$5.65 per share	N/A
XENE Xenon Pharmaceuticals	$7.50M	490.05	N/A	N/A	$7.53 per share	5.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPMUF Basilea Pharmaceutica	$48.57M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	$66.35M	$1.41	32.49	29.75	N/A	20.37%	9.26%	8.61%	11/3/2026 (Estimated)
VKTX Viking Therapeutics	-$359.64M	-$4.66	N/A	N/A	N/A	N/A	-94.56%	-82.75%	10/28/2026 (Estimated)
XENE Xenon Pharmaceuticals	-$345.91M	-$4.74	N/A	N/A	N/A	N/A	-43.98%	-41.72%	11/2/2026 (Estimated)

Latest BPMUF, VKTX, XENE, and VCYT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/2/2026	Q3 2026	XENE Xenon Pharmaceuticals	-$1.17	N/A	N/A	N/A	$1.33 million	N/A
10/28/2026	Q3 2026	VKTX Viking Therapeutics	-$1.07	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	XENE Xenon Pharmaceuticals	-$1.16	-$1.11	+$0.05	-$1.11	$1.67 million	N/A
7/30/2026	Q2 2026	VCYT Veracyte	$0.4103	$0.54	+$0.1297	$0.31	$144.59 million	$150.32 million
7/29/2026	Q2 2026	VKTX Viking Therapeutics	-$1.21	-$1.10	+$0.11	-$1.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPMUF Basilea Pharmaceutica	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPMUF Basilea Pharmaceutica	N/A	N/A	N/A
VCYT Veracyte	N/A	9.16	8.80
VKTX Viking Therapeutics	N/A	4.72	4.72
XENE Xenon Pharmaceuticals	N/A	21.01	21.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPMUF Basilea Pharmaceutica	N/A
VCYT Veracyte	N/A
VKTX Viking Therapeutics	76.03%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
BPMUF Basilea Pharmaceutica	N/A
VCYT Veracyte	1.60%
VKTX Viking Therapeutics	5.30%
XENE Xenon Pharmaceuticals	2.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPMUF Basilea Pharmaceutica	189	13.17 million	N/A	Not Optionable
VCYT Veracyte	755	80.39 million	79.11 million	Optionable
VKTX Viking Therapeutics	65	125.99 million	119.31 million	Optionable
XENE Xenon Pharmaceuticals	364	96.67 million	93.85 million	Optionable

BPMUF, VKTX, XENE, and VCYT Headlines

Recent News About These Companies

Xenon CFO buys 15,000 shares

October 4 at 4:02 AM | americanbankingnews.com

Xenon Pharmaceuticals (NASDAQ:XENE) Stock: Insider Ian Mortimer Purchases 30,000 Shares

October 3 at 4:22 AM | americanbankingnews.com

Xenon Pharmaceuticals (NASDAQ:XENE) Stock: Insider Thomas Patrick Kelly Buys 15,000 Shares

October 3 at 4:22 AM | americanbankingnews.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Rating of "Moderate Buy" from Brokerages

October 3 at 3:03 AM | americanbankingnews.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of "Moderate Buy" from Brokerages

October 3 at 2:28 AM | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Shares Climb 5.2% After Insider Buying Activity

October 3 at 2:24 AM | americanbankingnews.com

Wall Street Zen Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to "Sell"

October 3 at 1:48 AM | americanbankingnews.com

Xenon Pharmaceuticals (NASDAQ:XENE) Stock Lifted to "Sell" by Wall Street Zen

October 3 at 1:17 AM | marketbeat.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2 at 4:11 PM | financialpost.comF

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2 at 4:01 PM | globenewswire.com

Insider Buying: Xenon Pharmaceuticals (NASDAQ:XENE) CFO Buys $559,800.00 in Stock

October 2 at 5:07 AM | insidertrades.com

Xenon's AZK Approval Path Unlikely to Be Hurt by Safety Issues, RBC Says

October 1, 2026 | finance.yahoo.com

Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month

October 1, 2026 | finance.yahoo.com

Xenon Pharmaceuticals (NASDAQ:XENE) Shares Up 5.2% Following Insider Buying Activity

October 1, 2026 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) CFO Thomas Patrick Kelly Buys 15,000 Shares of Stock

October 1, 2026 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Stock: Insider Ian Mortimer Buys 30,000 Shares

October 1, 2026 | marketbeat.com

Defence Therapeutics names ex-Xenon CFO Sherry Aulin to its board

September 29, 2026 | streetinsider.com

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors

September 29, 2026 | newsfilecorp.comN

Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review

September 27, 2026 | marketbeat.com

Bank of America Corp DE Buys New Holdings in Xenon Pharmaceuticals Inc. $XENE

September 24, 2026 | marketbeat.com

XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law

September 22, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BPMUF, VKTX, XENE, and VCYT Company Descriptions

Basilea Pharmaceutica OTCMKTS:BPMUF

$76.25 0.00 (0.00%)

As of 10/2/2026 10:31 AM Eastern

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.

Veracyte NASDAQ:VCYT

$45.81 0.00 (0.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$45.86 +0.04 (+0.10%)

As of 10/2/2026 07:30 PM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Viking Therapeutics NASDAQ:VKTX

$29.94 0.00 (0.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$30.02 +0.07 (+0.25%)

As of 10/2/2026 07:59 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Xenon Pharmaceuticals NASDAQ:XENE

$38.02 0.00 (0.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$38.05 +0.03 (+0.08%)

As of 10/2/2026 07:32 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BPMUF, VKTX, XENE, and VCYT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BPMUF, VKTX, XENE, and VCYT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BPMUF, VKTX, XENE, and VCYT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BPMUF, VKTX, XENE, and VCYT Company Descriptions

Basilea Pharmaceutica OTCMKTS:BPMUF

Veracyte NASDAQ:VCYT

Viking Therapeutics NASDAQ:VKTX

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BPMUF, VKTX, XENE, and VCYT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BPMUF, VKTX, XENE, and VCYT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BPMUF, VKTX, XENE, and VCYT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BPMUF, VKTX, XENE, and VCYT Company Descriptions

Basilea Pharmaceutica OTCMKTS:BPMUF

Veracyte NASDAQ:VCYT

Viking Therapeutics NASDAQ:VKTX

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools